Recent data from the STEP UP trial exploring a higher 7.2 mg dose suggests additional weight loss is possible with dose escalation, but the standard 2.4 mg remains the benchmark
Theyre more likely to cause discomfort, inflammation, or even pain during or after the injection, which can make regular dosing unpleasant and less sustainable
For immediate energy effects, NAD+ wins
Whilst modest heart rate increases are expected with GLP-1 receptor agonists and generally do not require intervention, patients should be aware of symptoms that warrant medical attention
These compounds are celebrated for their capabilities in hindering the growth of fat cells, promoting the breakdown of fats, and reducing the formation of new fat cells, offering promising avenues for addressing metabolic issues [28, 48]
( I ) Scheme depicting the investigation of the long-term effect of GLP-1R knockdown in the dLS on liraglutide-induced weight loss